Beyond Oncology: Advancing Precision Medicine with Deep Patient Data
Precision medicine is at a turning point. For years, oncology has led the way, leveraging genomics to match targeted therapies to specific patient characteristics. Now, the availability of deep, multimodal patient data and the AI tools needed to interpret them are poised to expand precision medicine across therapeutic areas.
Moving Beyond Oncology
Oncology’s success in precision medicine has been largely driven by genetic sequencing, enabling targeted therapies. However, many diseases—such as cardiometabolic, neurological, and autoimmune conditions—are polygenic, shaped by multiple genetic factors, making precision approaches more complex.
To achieve similar breakthroughs across therapeutic areas, we need to harness the full spectrum of clinical data. The key is accessing rich, multimodal patient data that have long existed in the healthcare system but remained largely out of reach and undecipherable for research at scale. These data can improve patient phenotyping for more effective therapies, inform risk prediction and personalized treatment options, and power the development of novel biomarkers.
The Limits of Traditional Data
Life sciences companies have historically relied on two valuable but imperfect data sources:
Randomized Controlled Trials (RCTs): Offer strong causal insights but within artificial constraints—study populations rarely reflect real-world diversity, and controlled environments mask actual treatment patterns.
Traditional Real-World Data (RWD): Provides breadth but lacks depth—claims and structured EHR data are designed for billing, not scientific discovery, leaving disease complexity and treatment responses hidden.
This data gap has been a fundamental barrier to expanding precision medicine.
A New Era of Deep Clinical Data
Two breakthroughs are changing the game:
Access to comprehensive clinical data across modalities—including unstructured notes, imaging, diagnostics, and longitudinal records.
Advanced AI capabilities that extract meaningful insights from this complex data at scale.
Dandelion’s platform integrates clinical trial-level depth with real-world evidence to create a nuanced, longitudinal view of patient care. With access to deeper, multimodal clinical data from diverse data sources, researchers are no longer limited by available datasets. Instead, they can ask the right scientific and commercial questions—and answer them with confidence.
This enables life sciences companies to:
Identify patient subgroups most likely to benefit from specific therapies.
Understand disease progression and treatment response patterns.
Design more representative trials with meaningful endpoints.
Build stronger evidence packages for regulatory and commercial success.
This approach streamlines clinical development, reduces costs, and increases success rates across the asset lifecycle.
The Future of Precision Medicine
By making deep clinical data accessible and interpretable at scale, we can drive discovery across therapeutic areas once considered too complex for precision approaches.
At Dandelion, we’re catalyzing this shift. Our platform delivers the two essential ingredients for next-generation precision medicine: comprehensive clinical data and AI-powered interpretation.
The data exists. The tools are here. Now, it’s time to make it actionable.
Explore how deep clinical data can transform your approach to precision medicine.
